15th week of 2015 patent applcation highlights part 29 |
Patent application number | Title | Published |
20150098897 | COMBINATION TUMOR TREATMENT WITH DRUG-LOADED, BISPECIFIC LIGAND-TARGETED MINICELLS AND INTERFERON-GAMMA - Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents. | 2015-04-09 |
20150098898 | PHARMACEUTICAL COMPOSITION, METHOD AND KIT FOR DETECTING HUMAN MELANOMA CELLS - The present disclosure is related to a pharmaceutical composition for detecting human melanoma cells, including: a liposome, a biomolecule having specificity for α | 2015-04-09 |
20150098899 | Particulate Materials And Compositions For Radio Therapy - Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of various cancers. The benefit of bioresorption, the ability to control the ratio of radioisotopes in the particulate, especially the gamma and beta ratios such as In-111/Y-90 ratio in a particulate, and the benefit of non-conductive implants are disclosed. | 2015-04-09 |
20150098900 | ANTI-FCRH5 ANTIBODIES - The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same. | 2015-04-09 |
20150098901 | Actinium-225 Compositions of Matter And Methods Of Their Use - The present invention is directed to improved methods for generating compositions comprising actinium-225. | 2015-04-09 |
20150098902 | Fluorinated 2-Amino-4-(Benzylamino)Phenylcarbamate Derivatives - The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described. | 2015-04-09 |
20150098903 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders - One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera. | 2015-04-09 |
20150098904 | EYE DROP COMPOSITION - The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals. | 2015-04-09 |
20150098905 | METHODS TO DETECT A FUNGAL CELL - The present invention relates to targeting agents and methods: of using the targeting agents to detect a fungal cell in a subject. | 2015-04-09 |
20150098906 | MEDICINALLY MARKED ROLLING PAPERS - A method of manufacturing a cigarette and its constituent components including one or more formulations of filler materials and one or more rolling papers each printed with indicia indicative of the respective formulations of filler material. Also the provision of printed material that associates the particular indicia with its associated formulation. | 2015-04-09 |
20150098907 | FOAMABLE COMPOSITION AND USES THEREOF - The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%;or about 10% to about 20%; or about 20% to about 50% by weight; about 0.1% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and (5) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. | 2015-04-09 |
20150098908 | Biolubricant Polypeptides and Therapeutic Uses Thereof - The invention relates to the field of medicine. In particular, it relates to recombinant cationic polypeptides and their use as biolubricant. Provided is a biolubricant substance comprising the amino acid sequence[(GKGVP)9] | 2015-04-09 |
20150098909 | SOLUBLE FIBER LOZENGE - A soluble fiber lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and one or more additives dispersed in the soluble-fiber matrix. In some cases, a soluble fiber lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in soluble fiber lozenge provided herein can include maltodextrin. The soluble fiber lozenge is adapted to release one or more additives from the body when the body is received within the oral cavity of a consumer and exposed to saliva. A method of making soluble fiber lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, one or more additives, and less than 15 weight percent water while maintaining a mixture temperature of less than 200° C. and portioning the molten mixture into a plurality of soluble fiber lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder. | 2015-04-09 |
20150098910 | BIOFILM DISRUPTIVE COMPOSITIONS - In certain embodiments, the present invention relates to compounds, compositions, and methods for disrupting biofilms. In some embodiments, the compounds and compositions comprise unsaturated long chain alcohols and/or aldehydes, or combinations of such compounds. In further embodiments, the present invention contains therapeutic actives to help reduce and/or eradicate the bacteria in the biofilm once the film is disrupted. | 2015-04-09 |
20150098911 | Oral Composition - Provided is an oral composition that can sufficiently remove protein staining present on a tooth surface, can effectively prevent adhesion of protein staining on a tooth surface and can provide a good actual feeling of the cleaning effect in the oral cavity. The oral composition comprises the following components (A) and (B): (A) an N-acylamino acid or a salt thereof in an amount of 0.005 mass % or more and 0.3 mass % or less; and (B) pyrophosphoric acid or a salt thereof in an amount of 0.005 mass % or more and 0.5 mass % or less, in which a mass ratio ((B)/(A)) of the component (B) to the component (A) is 0.05 or more and 40 or less and a total content of the component (A) and the component (B) is 0.01 mass % or more and 0.6 mass % or less. | 2015-04-09 |
20150098912 | BRANCHED POLYETHER-POLYAMIDE BLOCK COPOLYMERS AND METHODS OF MAKING AND USING THE SAME - Described herein is a polyether polyamide block copolymer as well compositions and products containing the polyether polyamide block copolymer. Methods of making and using the copolymer, the compositions, and products are also described herein. | 2015-04-09 |
20150098913 | SUNSCREEN REAPPLICATION REMINDER DEVICE AND METHOD - In one general aspect, an apparatus for managing exposure to the sun is disclosed. It includes an aquatic activity control responsive to user interaction and an aquatic activity indicator associated with the aquatic activity control and operative to identify the aquatic activity control. It also includes a terrestrial activity control responsive to user interaction and a terrestrial activity indicator associated with the terrestrial activity control and operative to identify the terrestrial activity control. Timer logic is responsive to the aquatic activity control and the terrestrial activity control and it is operative to measure different predetermined sunscreen-product-specific time durations for a predetermined sunscreen product corresponding to sunlight exposure limits for aquatic or terrestrial activities in response to respective actuation of the aquatic activity control or the terrestrial activity control. An alert transducer is responsive to the timer logic, and a water-resistant housing is provided for at least part of the aquatic activity control, the terrestrial activity control, and the timer logic. | 2015-04-09 |
20150098914 | GLUCURONOLACTONE DERIVATIVES AS SELF-TANNING SUBSTANCES - The invention relates to the use of specific glucuronolactone derivatives as self-tanning substances, as tanning enhancers for dihydroxyacetone or for a mixture of self-tanning substances comprising dihydroxyacetone, for modulation of the colour shade achieved in the case of tanning with dihydroxyacetone or by the mixture or preparation comprising dihydroxyacetone, as contrast-reduction agents or for colouring keratin-containing fibres, and to preparations or compositions for colouring keratin-containing fibres comprising these specific glucuronolactone derivatives. | 2015-04-09 |
20150098915 | NOVEL SURFACTANT-FREE SELF-REVERSIBLE REVERSE LATEX, AND USE OF SAME AS A THICKENING AGENT IN A COSMETIC COMPOSITION - Disclosed is a self-reversible reverse latex including: a) 25-80% by mass of a cross-linked anionic polyelectrolyte (P), resulting from the polymerisation, for 100 mole percent: i)—of a molar proportion 30% and 95% of monomeric units from at least one monomer including a free, partially- or totally-salified strong acid function; and ii)—of a molar proportion >0% and <5% of at least one monomer with diethylenic or polyethylenic crosslinking; b) 0.5-10% by mass of a terpolymer of stearyl methacrylate, pentacosaethoxylated behenyl methacrylate and N,N-dimethylacrylamide, resulting from the polymerisation, for 100 mole percent: of 80-95 mole percent of stearyl methacrylate, of 2.5-10 mole percent of N,N-dimethylacrylamide, and of 2.5-10 mole percent of pentacosaethoxylated behenyl methacrylate, c) 5-40% by mass of at least one oil, and d) 0.1-40% by mass of water; method of preparing same and use thereof as a thickener. | 2015-04-09 |
20150098916 | SUNSCREEN COMPOSITIONS CONTAINING AN ULTRAVIOLET RADIATION-ABSORBING POLYESTER - Compositions including an oil phase emulsified in a continuous water phase, the oil phase including a sunscreen agent that includes a UV-absorbing polyester in an amount effective to provide the composition with an SPF of about 10 or greater and which is the polymerization reaction product of monomers including a UV-absorbing triazole, a diester, a diol and a tetrol polyol; an anionic oil-in-water emulsifier, and a nonionic oil-in-water emulsifier having an alcohol functional group, where the weight ratio of the anionic emulsifier to the nonionic emulsifier is about 2 or less and where the composition is substantially free of a non-polymeric UV-absorbing sunscreen agent and will have an SPF of less than 2 in the absence of the UV-absorbing polyester. | 2015-04-09 |
20150098917 | METHOD FOR PREVENTING OR TREATING SKIN TUMOR - Methods, compositions and products for preventing skin tumor formation or inhibiting the development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an α2 adrenergic receptor agonist, such as brimonidine. | 2015-04-09 |
20150098918 | CREAM GELS COMPRISING AT LEAST ONE RETINOID AND BENZOYL PEROXIDE - Stable cream gel dermatological/cosmetic compositions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one lipophilic compound and at least one gelling agent. | 2015-04-09 |
20150098919 | SKIN LIGHTENING FORMULATIONS - A skin care formulation which provides a skin lightening effect virtually immediately upon topical application to the skin and which includes a combination of one or more poly(ethylene) oxides and an acrylic emulsion polymer film former comprising emulsion polymers derived from one or more ethylenically unsaturated monomers. | 2015-04-09 |
20150098920 | Personal Cleansing Compositions and Methods - A personal care composition includes a surfactant, a water soluble cationic polymer, a hydrophobic benefit agent, and a hydrophobic cationic polyethylene polymer. | 2015-04-09 |
20150098921 | DIHYDROXYALKYL SUBSTITUTED POLYGALACTOMANNAN, AND METHODS FOR PRODUCING AND USING THE SAME - Disclosed are compositions including dihydroxyalkyl substituted polygalactomannan, and the optional further substitution of such with cationic and/or hydrophobic moieties. Method of making such compositions is also disclosed as well as the use of such compositions in industrial applications, fabric laundering, and personal and household care. | 2015-04-09 |
20150098922 | COMPOSITIONS COMPRISING POLYAMINE POLYMER COMPATIBLE PERFUME MATERIALS - Compositions comprising polyamine polymers and polyamine polymer compatible perfume materials, more specifically, perfume aldehydes that do not react with polyamine polymers are provided. | 2015-04-09 |
20150098923 | SOLID FORM SODIUM LAURYL SULFATE (SLS) CRAWLING PEST ELIMINATION COMPOSITION - A composition and method of eliminating pests combines water and a solid form of sodium lauryl sulfate to form a pesticide composition effective to cause mortality in pests. The composition is applied to the indoor structure in an area which the pests inhabit. The sodium lauryl sulfate can be in needle form, pellet form or powder form and constitutes between about 1% and about 10% by weight of the pesticide composition. The composition may be applied to an area inhabited by cockroaches, including, but not limited to, in crevices, cracks, corners, wall and floor junctures or other enclosed or partially enclosed areas of a structure. | 2015-04-09 |
20150098924 | METHOD FOR EX-VIVO PURGING IN AUTOLOGOUS TRANSPLANTATION - The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (ASCT) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating Hodgkin's disease. Such therapy is nowadays also contemplated for selected patients with low-grade lymphomas (chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma) and for patients with acute myeloid leukemia (AML). Current treatments for cell purging include chemotherapy and antibody cocktails. These treatments are often toxic on stem cells and not efficient in eliminating cancer cells. Thus, there is an unmet medical need for cell purging in ASCT which this project will address. | 2015-04-09 |
20150098925 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES USING DISEASE-SPECIFIC PROMOTER - The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microRNA, siRNA or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that the promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body. The disease-specific promoter may be the promoter of the LOX1 gene. The therapeutic agent may be Interleukin 10 (IL10). | 2015-04-09 |
20150098926 | Methods of Treating Hepatitis C Virus Infection - The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. Also provided are methods of treating liver steatosis and liver fibrosis. | 2015-04-09 |
20150098927 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER - The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoKβ) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoKβ) for the treatment of cancer as well as to methods for determining the prognosis of a patient based on the determination of the ChoKβ expression levels as well as based on the determination of the relationship between the ChoKβ and ChoKα expression levels. Finally, the invention relates to methods for determining the response of a patient who suffers from cancer to ChoKα-inhibiting agents based on the determination of the PEMT and/or ChoKβ expression levels. | 2015-04-09 |
20150098928 | ISOXAZOLINE INSECTICIDES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, | 2015-04-09 |
20150098929 | Probiotic Formulation - A probiotic organism which is capable of proliferation in iron-rich media, an environment which is generally unfavourable to probiotic organisms, is described. | 2015-04-09 |
20150098930 | Diabetic Nutritional Composition - The present invention provides nutritional compositions as powders, lozenges, tablets or liquids that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the human system, and specifically for those humans predisposed to, or suffering from, the diabetic human condition. It is believed that the key ingredients of the present invention work synergistically together to aid in the slowing, stopping, or reversing the symptoms and metabolic disorder characteristic of the human diabetic condition. These essential components are comprised of uniquely-selected minerals, phytonutrients and vitamin combinations. | 2015-04-09 |
20150098931 | Cooperative Medication Combination Systems - This invention aims to capture and teach the high-level concept of combining doses of medications in unconventionally substandard amounts, for the treatment of medical. pathologies. By combining multiple medications each of which is aimed at treating the same disease process and each in a given substandard dosage, it should allow for greater comprehensive efficacy while simultaneously bypassing side-effects, clinically significant medication interactions; and other potentially unforeseen deleterious effects, all because the dosage is small enough and collaborative chemical diversity manifests favorable kinetic dynamics, thereby mitigating unwanted drug effects. | 2015-04-09 |
20150098932 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO - Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen. | 2015-04-09 |
20150098933 | TRUNCATED LYSOSOMAL ACID LIPASE - Recombinant human lysosomal acid lipase (rhLAL) containing an N-terminal truncation, a composition of truncated recombinant human LAL (TLAL), an isolated mixture comprising TLAL and at least one other form of rhLAL are disclosed. A method of purifying TLAL from a mixture of LAL proteins, pharmaceutical compositions comprising TLAL and methods of producing TLAL are further disclosed. | 2015-04-09 |
20150098934 | Topical Preparations Comprising Grape Seed, Folic Acid, Biotin, Bifidobacterium longum and Echinacea purpurea - Topical compositions comprising grape seed and at least three of folic acid, biotin, | 2015-04-09 |
20150098935 | Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization - In this application Is described a composition and method for Inducing In a subject anti-hapten antibodies without Inducing antibodies to the carrier protein. Kits for designing and making compositions with desired haptens are also described. In this application Is disclosed a synthetic liposome composition comprising liposomes (L) containing monophosphoryl lipid A (MPLA) [L(MPLA)] and an immunoconjugate comprising a carrier and a hapten. In one embodiment, the carrier is a 23 amino acid hydrophobic membrane proximal external region peptide (MPER) derived from the gp41 transmembrane protein of HIV-1 that spontaneously associates with the outer surface of bilayers of liposomes containing MPLA during liposome formation. | 2015-04-09 |
20150098936 | REIMMUNIZATION AND ANTIBODY DESIGN - The present invention relates to methods for harvesting of antibodies from an antibody library. The antibodies are harvested by utilising a certain epitope that is analogous to the epitope of the antigen used for immunization but that may differ in global physical and biochemical properties allowing the production of antibodies against antigens that normally cannot be utilised as immunizing agents. The present invention furthermore relate to fields of use for harvested antigens in industry, agriculture and healthcare. | 2015-04-09 |
20150098937 | IDENTIFICATION OF GENETIC VARIANTS - The present disclosure provides a method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the presence or absence of an allelic variant indicates whether the subject is more or less likely to be responsive to VEGF-based therapy. | 2015-04-09 |
20150098938 | Modulators of ACYL-COA Lysocardiolipin Acyltransferase 1 (ALCAT1) and Uses Thereof - Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided. | 2015-04-09 |
20150098939 | NOVEL ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF - The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used. | 2015-04-09 |
20150098940 | Biomarkers for Systemic Lupus Erythematosus Disease Activity, and Intensity and Flare - The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided. | 2015-04-09 |
20150098941 | Anti-Glypican-3 Antibody - An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention. | 2015-04-09 |
20150098942 | CANCER TREATMENT AND MONITORING METHODS USING OX40 AGONISTS - OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation. | 2015-04-09 |
20150098943 | PROTEIN CONSTRUCTS DESIGNED FOR TARGETING AND LYSIS OF CELLS - The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a heteromultimeric protein, is useful for redirecting an immune response that was pre-existing in a patient, toward an undesired target cell. | 2015-04-09 |
20150098944 | FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS - Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker. | 2015-04-09 |
20150098945 | ANTI-ROBO4 ANTIBODY - The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenic effects in in-vivo models. | 2015-04-09 |
20150098946 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein. | 2015-04-09 |
20150098947 | MONOCLONAL OLFML-3 ANTIBODIES AND USES THEREOF - Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments. | 2015-04-09 |
20150098948 | Compositions And Methods For The Therapy And Diagnosis Of Influenza - The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. | 2015-04-09 |
20150098949 | VEGF/DLL4 Binding Agents and Uses Thereof - The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 2015-04-09 |
20150098950 | LIQUID FORMULATIONS OF TUMOR NECROSIS FACTOR-BINDING PROTEINS - The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent. | 2015-04-09 |
20150098951 | MODULATORS OF CANDIDA HYPHAL MORPHOGENESIS AND USES THEREOF - The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof. | 2015-04-09 |
20150098952 | NOVEL THERAPEUTIC TARGET AND DIAGNOSTIC MARKER FOR ASTHMA AND RELATED CONDITIONS - CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression. | 2015-04-09 |
20150098953 | METHODS OF TREATING A PATIENT HAVING AN AUTOIMMUNE DISORDER BY ADMINISTERING A BAFF ANTAGONIST - Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorder are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round or administration. | 2015-04-09 |
20150098954 | Compositions and Methods Related to CRISPR Targeting - Disclosed herein include embodiments related to addition, deletion, or modification of DNA, RNA, or protein in a subject. In an embodiment, the DNA, RNA, or protein is endogenous. In an embodiment, the DNA, RNA, or protein is exogenous. Further embodiments relate to computerized systems for assisting in the disclosed methods. | 2015-04-09 |
20150098955 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS AND METHODS OF USE THEREOF - The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions. | 2015-04-09 |
20150098956 | RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II a1 DOMAINS - Recombinant polypeptides comprising a DRα1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides. | 2015-04-09 |
20150098957 | PCSK9 VACCINE - The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 2015-04-09 |
20150098958 | Influenza Nucleoprotein Vaccines - The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from Influenza strain A, B or C, and a variant of a C4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from Influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease. | 2015-04-09 |
20150098959 | Mucosal Immunity-Stimulating Agent, and Oral Pharmaceutical Composition for Treating HPV Infection - A mucosal immunity-stimulating agent contains a Kampo preparation having a revitalizing activity and a mucosal adjuvant. An oral pharmaceutical composition for treating HPV infection contains at least HPV E7 polypeptide and a Kampo preparation having a revitalizing activity. | 2015-04-09 |
20150098960 | TREATMENT OF CANCERS WITH IMMUNOSTIMULATORY HIV TAT DERIVATIVE POLYPEPTIDES - Disclosed herein are compositions comprising a Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) derivative polypeptide with increased immunostimulatory properties relative to the native Tat polypeptide, pharmaceutical compositions comprising the Tat derivative polypeptide, and methods of treating cancer using the Tat derivative polypeptide. | 2015-04-09 |
20150098961 | Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits - The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic | 2015-04-09 |
20150098962 | MODULATORS OF CANDIDA HYPHAL MORPHOGENESIS AND USES THEREOF - The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof. | 2015-04-09 |
20150098963 | METHODS AND COMPOSITIONS FOR IMPROVING THE APPEARANCE OF SKIN - A method for stimulating collagen synthesis in aging skin cells in need of treatment by topically applying a composition comprising at least one extract from | 2015-04-09 |
20150098964 | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING LISTERIA VACCINE TREATMENT - This invention provides methods and compositions for using a live attenuated | 2015-04-09 |
20150098965 | MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION - The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans. | 2015-04-09 |
20150098966 | Influenza vaccines - An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic. | 2015-04-09 |
20150098967 | ROTAVIRUS VACCINE COMPOSITIONS AND PROCESS FOR PREPARING THE SAME - Invention provides novel rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without requiring separate administration of an antacid before vaccine administration. Vaccine compositions with buffers of the invention are stable liquid rotavirus vaccine formulations for oral administration. | 2015-04-09 |
20150098968 | HAEMOPHILUS PARASUIS VACCINE SEROVAR TYPE FOUR - The present invention is a | 2015-04-09 |
20150098969 | ALTERNARIA PEPTIDES - Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the | 2015-04-09 |
20150098970 | Biomaterial and Methods of Use Thereof for the Prevention of Post-operative Adhesions - Biofunctional films and methods of use thereof for the prevention of post-operative adhesions are disclosed. | 2015-04-09 |
20150098971 | NAIL POLISH COMPOSITIONS - Personal care products for maintaining fingernail and toenail appearance. In particular, nail polish compositions that have a formulation that is both safer and more environmentally-friendly to use. The present nail polish compositions comprise anionic polyester resins such as sodio-sulfonated polyesters and sodio-sulfonated co-polyester-co-polysiloxane copolymers as base resin vehicles. | 2015-04-09 |
20150098972 | Coated, Wet-Chemically Oxidized Aluminum Effect Pigments, Method for the Production Thereof, Coating Agent and Coated Object - A coated wet-chemically oxidized aluminum effect pigment is provided having at least one metal oxide layer having at least one metal oxide which differs from aluminum oxide and an enveloping organic polymer layer, wherein the weight ratio of the metal oxide of the metal oxide layer to aluminum oxide in the wet-chemically produced aluminum oxide layer of uncoated wet-chemically oxidized aluminum effect pigment is in a range of from 1:1 to 1:40. Also, a method for the production of the pigment is provided. | 2015-04-09 |
20150098973 | COMPOSITION FOR APPLICATION TO THE SKIN COMPRISING SILSESQUIOXANE RESIN WAX AND SOLID PARTICULATE - Provided in various embodiments are compositions for topical application to the skin, comprising a silsesquioxane resin wax, at least one solid particulate with an average particle size greater than 1 micron, and one or more additional waxes. | 2015-04-09 |
20150098974 | Compositions, Methods of Making a Composition, and Methods of Use - Embodiments of the present disclosure, in one aspect, relate to compositions including a copper/silica nanocomposite and a polymer, methods of making a composition, methods of using a composition, and the like. | 2015-04-09 |
20150098975 | INSECTICIDAL WATER-IN-OIL (W/O) FORMULATION - The invention relates to an insecticidal water-in-oil (W/O) formulation with at least one insecticidal active substance and at least one burning salt and to the preparation of this formulation. The formulation according to the invention is particularly suitable for the treatment of suitable supports, in particular of paper supports, in an economical one-step process with the aid of conventional application processes. In addition, the present invention relates to insecticidal, smoulderable products which are prepared by treating a support with the formulation according to the invention. | 2015-04-09 |
20150098976 | ANTIMICROBIAL AND ANTIFOULING CATECHOL-CONTAINING POLYCARBONATES FOR MEDICAL APPLICATIONS - Catechol-bearing polycarbonates (catechol polymers) were prepared comprising i) a catechol repeat unit comprising a side chain catechol group, ii) a cationic repeat unit comprising a side chain cationic group selected from the group consisting of quaternary amine groups, quaternary phosphine groups, and combinations thereof, and iii) a PEG repeat unit comprising a side chain poly(ethylene oxide) group having a degree of polymerization of about 5 to about 30. The catechol polymers form antimicrobial and antifouling films on a variety of substrate surfaces, in particular silicone rubber. | 2015-04-09 |
20150098977 | IMPLANTABLE DEVICES FORMED OF NON-FOULING METHACRYLATE OR ACRYLATE POLYMERS - Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof. | 2015-04-09 |
20150098978 | DISSOLVABLE-CHEWABLE TABLET - A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissolved within an oral cavity. | 2015-04-09 |
20150098979 | METHOD FOR IMPARTING ENDURING BENEFICIAL FEATURES TO FLOCKED SURFACES - A method of imparting enduring beneficial features to a hard flocked surface of an article is provided. The method includes encapsulating a desired beneficial agent as a core material in a polymeric microcapsule, and transferring polymeric microcapsule to the surface by a dipping, spraying, or padding application. The beneficial agent, after getting transferred to the surface of a hard flocked article, imparts long lasting performance, provides fragrance and may protect an article from odor, insect, pest, fungi, bacteria, viruses, and the like. The polymeric microcapsules deliver long lasting benefits to surfaces with flocking, such as clothes hangers. Also described is a process for manufacture of flocked items with benefit delivering polymer microcapsules, without the need for binders or adhesives. Benefit agents are released with shear force on the flocked surface, so they are released when used and provide long-lasting performance. | 2015-04-09 |
20150098980 | Dexmedetomidine Transdermal Delivery Devices and Methods for Using the Same - Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices. | 2015-04-09 |
20150098981 | Methods and Compositions for Transdermal Delivery of a Non-Sedative Amount of Dexmedetomidine - Aspects of the invention include methods for applying to a subject a transdermal delivery device configured to deliver a non-sedative amount of a dexmedetomidine composition. In practicing methods according to certain embodiments, a non-sedative amount of a dexmedetomidine composition is transdermally applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to a subject. Also provided are transdermal delivery devices having a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices. | 2015-04-09 |
20150098982 | Methods and Compositions for Managing Pain Comprising Dexmedetomidine Transdermal Compositions - Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject experiencing pain. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. Also provided are transdermal delivery devices configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices. | 2015-04-09 |
20150098983 | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions - Aspects of the invention include methods of treating withdrawal syndrome by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a non-sedative amount of dexmedetomidine to a subject diagnosed as having withdrawal syndrome. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to treat withdrawal syndrome in the subject. Also provided are transdermal delivery devices configured to deliver a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices. | 2015-04-09 |
20150098984 | NANOLITHOGRAPHY USING LIGHT SCATTERING FROM PARTICLES AND ITS APPLICATIONS IN CONTROLLED MATERIAL RELEASE - The present disclosure provides hollow nanostructures, methods of forming thereof, and methods of delivery of further nanomaterials utilizing the hollow nanostructures. The hollow nanostructures can be formed by illuminating particles, such as spherical particles, to create a scattering pattern that can be captured on, for example, a photoresist. Thus formed nanoparticles can have a substantially frusto-conical shape that can be tailored based on a variety of factors, including, for example, particle size, particle shape, light exposure characteristics, and light polarization. | 2015-04-09 |
20150098985 | WOUND DRESSINGS FOR THE CONTROLLED RELEASE OF THERAPEUTIC - A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP). | 2015-04-09 |
20150098986 | Method for Producing Elastic Vesicles - A method for producing elastic vesicles enveloping active ingredients includes pre-emulsification of a formulation of elastic vesicles and a homogenization step. The pre-emulsification of a formulation of elastic vesicles includes heating and uniformly mixing water of a water phase of the formulation and active ingredients until the active ingredients completely dissolve in the water, and adding an oil phase of the formulation premixed with edge activators to accomplish the pre-emulsification. The homogenization step includes using a device for miniaturizing or nanometerizing particles to proceed with disruption and homogenization. | 2015-04-09 |
20150098987 | TRANS-RESVERATROL POLYSACCHARIDE, METHOD OF PRODUCING THEREOF, AND COMPOSITION COMPRISING THEREOF - An object of the present invention is to provide a trans-resveratrol derivative that resists isomerization to the cis-form. This object can be achieved by a method for producing a trans-resveratrol polysaccharide, the method comprising the step of bringing a trans-resveratrol glucoside into contact with sugar in the presence of γ-cyclodextrin glucanotransferase. | 2015-04-09 |
20150098988 | COMBINATION THERAPY FOR THE TREATMENT OF OVARIAN CANCER - This invention concerns methods of treating a patient diagnosed with a platinum-resistant ovarian cancer comprising administering to said patient an effective amount of an anti-VEGF antibody and a chemotherapeutic. | 2015-04-09 |
20150098989 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS - Compounds of general formula (I): R | 2015-04-09 |
20150098990 | PEPTIDES THAT TARGET DORSAL ROOT GANGLION NEURONS - The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy. | 2015-04-09 |
20150098991 | ORAL ADMINISTRATION - The present invention is within the field of administration of biopharmaceuticals. More specifically, the invention provides for oral administration of a compound comprising a moiety which confers a desired therapeutic activity; and a polypeptide moiety which binds to albumin. | 2015-04-09 |
20150098992 | COMPOSITE FORMULATION COMPRISING MULTI-UNIT SPHEROIDAL TABLET (MUST) ENCAPSULATED IN HARD CAPSULE AND METHOD FOR PREPARING SAME - Provided is a composite formulation comprising multi-unit spheroidal tablets (MUSTs) encapsulated in a hard capsule and a method for preparing same. The inventive hard capsule composite formulation can effectively charge the MUSTs in the limited space of the capsule, which allows charging a high dose of different pharmaceutically active ingredients in a capsule with a relatively small size, to thereby increase the productivity and render it readily administered to patients. Also, the capsule has a good dissolution rate because the pharmaceutically active ingredients contained in the capsule are separated from one another; therefore, the dissolution rates of the ingredients are less affected by one another. It may also be possible to maximize the therapeutic effects of the pharmaceutically active ingredients since the composite formulation has good stability. | 2015-04-09 |
20150098993 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES - The present invention describes a composition and a kit, each having a plurality of compounds, for use in the treatment of inflammatory joint diseases and chronic inflammatory connective tissue diseases, such as Rheumatoid Arthritis (RA). The invention also relates to a process of obtaining the composition and a method of treating diseases by administration of the compositions. | 2015-04-09 |
20150098994 | PHARMACEUTICAL COMPOSITIONS FOR SLEEP APNEA - Pharmaceutical compositions are provided for the pharmacological treatment of breathing disorders and, more specifically, to compositions containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concentrations across the period of sleep. | 2015-04-09 |
20150098995 | Tabletting Process - A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Particular anti-static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate. | 2015-04-09 |
20150098996 | NICOTINE LOZENGE - A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in a nicotine lozenge provided herein can include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder. | 2015-04-09 |